Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720149 | 0.85 | — | — | |
| SCHEMBL3007015 | 0.82 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL3007784 | 0.78 | — | — | |
| SCHEMBL3006863 | 0.74 | — | — | |
| Carbon Monoxide SCHEMBL1982955 | 0.74 | — | — | |
| SCHEMBL3011683 | 0.73 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL7539350 | 0.72 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL18641305 | 0.72 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL1929940 | 0.72 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL17157063 | 0.72 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260036897-A1 | REPAIR PROCESS FOR CLEAR DEFECTS ON EUV PSM MASKS | ZEISS CARL SMT GMBH (DE) | 2026-02-05 | — | — | US | claimed |
| WO-2025061949-A2 | METHOD AND DEVICE FOR MASK REPAIR | CARL ZEISS SMT GMBH (DE) | 2025-03-27 | — | — | WO | claimed |
| WO-2024223530-A1 | REPAIR PROCESS FOR CLEAR DEFECTS ON EUV PSM MASKS | CARL ZEISS SMT GMBH (DE) | 2024-10-31 | — | — | WO | claimed |
| EP-4434988-A1 | ß-LACTAMASE INHIBITOR INTERMEDIATE AND PREPARATION METHOD THEREFOR | Evopoint Biosciences Co., Ltd. (CN) | 2024-09-25 | — | — | EP | claimed |
| JP-2004534856-A | — | — | 2004-11-18 | — | — | JP | claimed |
| EP-1406853-A1 | PROCESS FOR THE RACEMIZATION OF ALCOHOLS | Degussa AG (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003008361-A1 | PROCESS FOR THE RACEMIZATION OF ALCOHOLS | DEGUSSA AG (DE) | 2003-01-30 | — | — | WO | claimed |
| EP-4688156-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260036897-A1 | REPAIR PROCESS FOR CLEAR DEFECTS ON EUV PSM MASKS | ZEISS CARL SMT GMBH (DE) | 2026-02-05 | — | — | US | disclosed |
| US-12459941-B2 | Tricyclic IRAK inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250230140-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-26 | — | — | US | disclosed |
| US-6303805-B1 | COMPLEX FOR OLEFIN OR STYRENE POLYMERIZATION PREPARED BY REACTING TRANSITION METAL COMPLEX AND COMPOUND HAVING AT LEAST TWO FUNCTIONAL GROUPS, HAVING STRUCTURE IN WHICH ANCILLARY LIGANDS OF COMPLEX ARE BRIDGED WITH SAID FUNCTIONAL GROUP | SAMSUNG GENERAL CHEMICAL CO., LTD. (KR) | 2001-10-16 | — | — | US | disclosed |
| US-6130332-A | USING A GROUP 8 METAL CATALYST AND ALDEHYDES OR KETONE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| EP-1035125-A2 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-1006120-A2 | Metallocene complexes and method of preparing the same | Samsung General Chemicals Co., Ltd. (KR) | 2000-06-07 | — | — | EP | disclosed |
| US-5792867-A | Method of alkylating of triazine derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0760369-A1 | PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0711760-A1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459941-B2 | Tricyclic IRAK inhibitors | IRAK1, IRAK2, IRAK3 | CYP3A4 4619/4885TDP1 174/4885ESR1 983/4885 |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CYP3A4 152/4885TDP1 3324/4885ESR1 1899/4885 |
| US-20260036897-A1 | REPAIR PROCESS FOR CLEAR DEFECTS ON EUV PSM MASKS | PML, MUS81, PSMD14 | CYP3A4 3623/4885TDP1 3667/4885ESR1 662/4885 |
| US-20250230140-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | LPAR3, LPAR2, LPAR1 | CYP3A4 3615/4885TDP1 3298/4885ESR1 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.